Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers
Autor: | Yingying Wang, Junping Shi, Hongyuan Zhou, Ti Zhang, Yan Ke, QiangLi, Wei Zhang, Bo Yang, Zewu Zhang, Zhiqiang Han, Tianqiang Song, Guanghao Li, Guangtai Cao |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Pyridones medicine.medical_treatment Immunology Dasatinib Pyrimidinones Piperazines Targeted therapy Olaparib chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Humans Immunology and Allergy Medicine Molecular Targeted Therapy Prospective Studies Aged Trametinib Chemotherapy business.industry High-Throughput Nucleotide Sequencing Immunotherapy Middle Aged Prognosis Combined Modality Therapy Survival Rate Regimen Biliary Tract Neoplasms chemistry Phthalazines Female Neoplasm Recurrence Local business V600E Follow-Up Studies medicine.drug |
Zdroj: | Cancer Immunology, Immunotherapy. 70:1001-1014 |
ISSN: | 1432-0851 0340-7004 |
Popis: | Chemotherapy is a standard regimen for advanced or relapsed biliary tract cancer (BTC) with a 5-year overall survival (OS) rate of approximately 5% and a median OS of less than a year. Targeted therapies and immunotherapy aimed at providing more personalized treatments for BTCs have been tested. The objective of this study was to evaluate the effects of targeted therapy and immunotherapy on advanced BTC patients. Twenty-four advanced/relapsed BTC patients were enrolled and examined with next-generation sequencing (NGS). Eight of them received NGS-guided targeted or immunotherapy, and the other 16 patients underwent routine chemotherapy. Comparison analysis of OS and objective response rate (ORR) was performed. IDH1, BRCA2, MAP2K1, and BRAF (V600E) were the major actionable genes mutated in this cohort. Patients who received NGS-guided therapy exhibited higher OS (not achieved vs. 6.5 months, p |
Databáze: | OpenAIRE |
Externí odkaz: |